Clinician Information and Referrals
Clinicians are on the front line to assess whether genetic tests are appropriate for patients. Together with genetic counselors, they will interpret and explain the test results, as well as review choices the patient must consider as a consequence of the analysis of their genetic information.
At the Englander Institute for Precision Medicine’s healthcare, our laboratory and bioinformatics teams use gene sequencing testing to identify and characterize candidate genes or pathways with clinical implications to aid in patient’s healthcare management.
The Institute specializes in whole exome sequencing testing using our EXaCT1 process to analyze the coding regions and intron/exon boundaries of 21,522 genes. We can perform this test on as little as 300ng of DNA from a number of different sample types including blood, buccal swabs, frozen tissue, FFPE tissue, and bone marrow. We sequence normal and tumor DNA from each patient on the Illumina HiSeq2500, and detect and report somatic alterations, such as point mutations, amplifications, and deletions at frequencies of 10% or higher. Accurate and sensitive confirmation of low-frequency mutations within a heterogeneous tumor sample is critical for clinical applications. We use confirmation assays, such as digital PCR or FISH, to validate our results.
Patients’ results are shared with a multi-institutional Precision Medicine tumor board, whose members review the results of patients’ genomic sequencing, medical history, radiology reports, and collaboratively arrive at a treatment recommendation that may include FDA-approved targeted therapies. The Precision Medicine Clinic then shares the treatment plan with the patient and his or her clinician.
Physicians at the EIPM’s Precision Medicine Clinic, led by Himisha Beltran, MD, are currently seeing patients with advanced or refractory cancer. Patients are enrolled at the Institute after informed consent through an IRB-approved protocol. To refer a patient to the Clinic, please follow the instructions below.
At this time, patients must have advanced or refractory cancer to participate in studies at the Englander Institute for Precision Medicine and be referred to our Precision Medicine clinic by their clinician.
To refer patients to the Caryl and Israel Englander Institute for Precision Medicine, please send an email to firstname.lastname@example.org with the following information: